North America Microbiome Therapeutics Market Size & Outlook
North America microbiome therapeutics market, 2018-2030 (US$M)
Related Markets
North America microbiome therapeutics market highlights
- The North America microbiome therapeutics market generated a revenue of USD 71.9 million in 2022.
- The market is expected to grow at a CAGR of 37.2% from 2023 to 2030.
- In terms of segment, c. difficile was the largest revenue generating application in 2022.
- C. difficile is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2023 to 2030.
North America data book summary
| Market revenue in 2022 | USD 71.9 million |
| Market revenue in 2030 | USD 901.1 million |
| Growth rate | 37.2% (CAGR from 2022 to 2030) |
| Largest segment | C. difficile |
| Fastest growing segment | C. difficile |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | C. difficile, Crohns disease, Inflammatory Bowel Disease, Diabetes |
| Key market players worldwide | Finch Therapeutics Group Inc, Vedanta |
Other key industry trends
- In terms of revenue, North America region accounted for 75.8% of the global microbiome therapeutics market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- North America is the fastest growing regional market and is projected to reach USD 901.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Microbiome Therapeutics Market Scope
Microbiome Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America microbiome therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to microbiome therapeutics market will help companies and investors design strategic landscapes.
C. difficile was the largest segment with a revenue share of 83.59% in 2022. Horizon Databook has segmented the North America microbiome therapeutics market based on c. difficile, crohns disease, inflammatory bowel disease, diabetes covering the revenue growth of each sub-segment from 2018 to 2030.
North America dominated the market in 2022 owing to presence of key market players, various initiatives undertaken by regulatory bodies for funding R&D, increasing awareness about the disease, and the emerging use of novel treatment.
Major players in the market, such as Seres Therapeutics Inc.; Finch Therapeutics Group, Inc.; Enterome; and Vedanta Biosciences, have a strong presence in North America. This can significantly improve the availability of therapeutics.
The presence of a strong pipeline of drugs and increasing number of clinical trials of drug candidates in the region are among the factors expected to accelerate market growth in North America. Moreover, increasing prevalence of diseases such as IBD, Crohn’s disease, and diabetes in the region is anticipated to boost the market growth.
Reasons to subscribe to North America microbiome therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America microbiome therapeutics market databook
-
Our clientele includes a mix of microbiome therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America microbiome therapeutics market , including forecasts for subscribers. This continent databook contains high-level insights into North America microbiome therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
North America microbiome therapeutics market size, by country, 2018-2030 (US$M)
North America Microbiome Therapeutics Market Outlook Share, 2022 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
